Cells

Overview

Intellia is derived from the Greek word, Entelia, meaning a situation of excellence; without any faults. Intellia is a leading genome editing company, focused on the development of proprietary, potentially curative therapeutics using a recently developed biological tool known as the CRISPR/Cas9 system. Intellia believes the CRISPR/Cas9 technology has the potential to transform medicine by permanently editing disease-associated genes in the human body with a single treatment course.

Mission

Developing potentially curative genome editing treatments that can positively transform the lives of people living with severe and life-threatening diseases.

 

Our Approach

Our combination of deep scientific expertise and clinical development experience, along with our leading intellectual property portfolio, puts Intellia in a unique position to unlock broad therapeutic applications of the CRISPR/Cas9 technology and create a new class of therapeutic products.

Cells

We believe we are well positioned to maximize the potential of the CRISPR/Cas9 system to develop therapeutics because of:

  • A strong product focus
  • Deep management expertise
  • Strong product-focused partnerships
  • A risk-mitigated approach to accelerate product development
  • Delivery expertise
  • Leading Intellectual Property Position

We are extending this foundational platform, and broadening and optimizing our pipeline, through strategic engagements with partners in industry and academia.

The Future of Medicine

Standing on the Shoulders of Scientific History to Create Medicine's Future

Intellia is not only a leading genome-editing company, but also has the right combination of people, assets and ambitious vision needed to take full advantage of the CRISPR/Cas9 technology’s attributes – high potency, specificity, simplicity of use, broad applicability, and multifunctional programmability – and accelerate the advancement of curative products into the clinic.

The promise of the CRISPR/Cas9 system is the driving force behind the creation of Intellia. Our founders have a shared belief that this technology offers the potential for us to develop curative therapeutic options for patients with chronic diseases by addressing the underlying cause of the disease. It can bring new hope and cures to people who now have nowhere to turn for help.

“The ability to alter host DNA in a precise way has the potential to unlock a substantial amount of unmet medical need heretofore untapped by existing technologies … the value of precisely correcting DNA is immeasurable if accomplished with precision and control.”
Piper Jaffrey report, May 19, 2015, “Gene Therapy 2.0: Primer on Genome Editing

Intellia_linebreak-new-2